e-learning
resources
Amsterdam 2015
Wednesday, 30.09.2015
Lung cancer therapy: clinical trials
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficiency of erythropoiesis-stimulating agents (ESA) in the treatment of chemotherapy-induced anemia in patients with lung cancer (LC)
Angelica Tiotiu (Vandoeuvre-les-Nancy, France), Angelica Tiotiu, Isabelle Clerc-Urmès, Yves Martinet
Source:
International Congress 2015 – Lung cancer therapy: clinical trials
Session:
Lung cancer therapy: clinical trials
Session type:
Poster Discussion
Number:
4842
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Angelica Tiotiu (Vandoeuvre-les-Nancy, France), Angelica Tiotiu, Isabelle Clerc-Urmès, Yves Martinet. Efficiency of erythropoiesis-stimulating agents (ESA) in the treatment of chemotherapy-induced anemia in patients with lung cancer (LC). Eur Respir J 2015; 46: Suppl. 59, 4842
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Imaging of complicated pneumonia: what is new?
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Imaging of eosinophilic lung disease
Related content which might interest you:
Risk factors of febrile neutropenia induced by chemotherapy in lung cancer patients
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC)
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Treatment of advanced non-small cell lung cancer with trofosfamide
Source: Annual Congress 2013 –Advances in the therapy of lung cancer
Year: 2013
Pulmonary function during lung cancer therapy: A retrospective analysis of patients treated with monotherapy or multimodal treatments
Source: International Congress 2016 – Clinical aspects of lung cancer
Year: 2016
Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Assesment of palliative care in lung cancer in Turkey (ASPECT study)
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Assessment of pain and nutritional status in patients suffering from lung cancer
Source: International Congress 2016 – Kaleidoscope of respiratory nursing
Year: 2016
Gene therapy with DDMC-p53 with or without cisplatin and microwave ablation. A future concept for local treatment in lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Chemotherapy in elderly patients with non-small-cell lung cancer in Tunisian respiratory department
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
The rate of curative intended therapy against recurrent lung cancer before and after introduction of a CT-based follow-up program
Source: Annual Congress 2013 –Quality management in thoracic oncology
Year: 2013
Poor prognostic factors in advanced pulmonary adenocarcinoma patients receiving first-line gefitinib
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Influence of anxiety and depression on one-year survival in lung cancer patients
Source: International Congress 2016 – Quality management and quality of life in lung cancer
Year: 2016
Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Muldisciplinary conference (MDC), oncological program (OP) and practice guidelines (GL): The experience of the lung cancer (LC) clinic of a cancer hospital
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014
Prognostic factors for stage IV lung adenocarcinoma patients receiving retreatment with EGFR-TKI
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Site of first progression (PR) differs between stage III NSCLC patients treated with simultaneous radiochemotherapy (RTCT) and those treated with radiotherapy (RT) alone following induction chemotherapy (CT)
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014
Erlotinib (E) in elderly pts with NSCL: Experience at a tertiary referral center
Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases
Year: 2013
Survival in lung cancer: Associated factors in Tunisian patients
Source: International Congress 2015 – Thoracic oncology around the world: rare cases and local features
Year: 2015
Bevacizumab (Bv) in elderly pts with NSCLC: Experience at a tertiary referral center
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept